599PA VALIDATION OF CURRENT PROGNOSTIC SCORES IN METASTATIC COLORECTAL CANCER (MCRC) AND A NEW PROGNOSTIC SCORE (A GEMCAD STUDY)

599PA VALIDATION OF CURRENT PROGNOSTIC SCORES IN METASTATIC COLORECTAL CANCER (MCRC) AND A NEW PROGNOSTIC SCORE (A GEMCAD STUDY)

Abstract Aim: Background: The two main prognostic scores for mCRC (Kohne and GERCOR) do not account for resectability of liver-only metastasis (LiM) and thus are limited as treatment guidance. We propose a classification of patients based on LiM resectability, performance status (PS) and lactate deh...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of oncology 2014-09, Vol.25 (suppl_4), p.iv204-iv204
Hauptverfasser: Alonso-Orduna, V., Marmol, M., Escudero, P., Salud, A., Safont, M.J., Méndez, J.C., Girón, C. García, Martín, M., Fernandez-Martos, C., Albéniz, X. García, Feliu, J., Maurel, J.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page iv204
container_issue suppl_4
container_start_page iv204
container_title Annals of oncology
container_volume 25
creator Alonso-Orduna, V.
Marmol, M.
Escudero, P.
Salud, A.
Safont, M.J.
Méndez, J.C.
Girón, C. García
Martín, M.
Fernandez-Martos, C.
Albéniz, X. García
Feliu, J.
Maurel, J.
description Abstract Aim: Background: The two main prognostic scores for mCRC (Kohne and GERCOR) do not account for resectability of liver-only metastasis (LiM) and thus are limited as treatment guidance. We propose a classification of patients based on LiM resectability, performance status (PS) and lactate dehydrogenase (LDH) levels and compare its discrimination capacity against Kohne and GERCOR scores. Methods: We analyzed 395 patients treated with first-line oxaliplatin-based regimes with or without monoclonal antibodies. Patients were classified as stage 1 if LiM were considered resectable ( 1.5 ULN. This score, Kohne, and GERCOR scores were tested for discrimination using Harrel's C index (HCI, higher is better) and calibration using Akaike information criterion (AIC, smaller is better) of progression-free survival (PFS) and overall survival (OS). Results: Group 1Group 2Group 3GEMCADN78206111PFS HR (95% CI)1 (Reference)2.07 (1.54-2.78)2.98 (2.15-4.13)PFS HCI (95% CI)0.66 (0.60-0.73)PFS AIC3496.2OS HR (95% CI)1 (Reference)2.14 (1.52-3.00)3.68 (2.55-5.32)OS HCI (95% CI)0.68 (0.62-0.73)OS AIC2903.7KohneN15920531PFS HR (95% CI)1 (Reference)1.55 (1.23-1.93)2.86 (1.89-4.31)PFS HCI (95% CI)0.62 (0.56-0.68)PFS AIC3515.7OS HR (95% CI)1 (Reference)1.63 (1.27-2.10)4.57 (2.93-7.13)OS HCI (95% CI)0.65 (0.60-0.71)OS AIC2915.4GERCORN116153126PFS HR (95% CI)1 (Reference)1.40 (1.08-1.82)2.04 (1.55-2.68)PFS HCI (95% CI)0.60 (0.54-0.66)AIC3517.7OS HR (95% CI)1 (Reference)2.19 (1.62-2.96)3.21 (2.34-4.40)OS HCI (95% CI)0.66 (0.62-0.71)OS AIC2898.4 Conclusions: Conclusions. GEMCAD score performs as well, if not better, than Kohne and GERCOR scores and allows treatment guidance. Disclosure: All authors have declared no conflicts of interest.
doi_str_mv 10.1093/annonc/mdu333.101
format Article
fullrecord <record><control><sourceid>oup</sourceid><recordid>TN_cdi_oup_primary_10_1093_annonc_mdu333_101</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/annonc/mdu333.101</oup_id><sourcerecordid>10.1093/annonc/mdu333.101</sourcerecordid><originalsourceid>FETCH-oup_primary_10_1093_annonc_mdu333_1013</originalsourceid><addsrcrecordid>eNqVz09LAzEQh-EgCq7aD-Btji24Nmm61RyH2bRd2E1KklY8hcU_oNht6dKDNz96t9SbJ08DD8MPXsZuBb8XXMlh3TSb5mW4ft1LKTsSZywR2USlj3wszlnC1UimD5kcX7Krtv3knE_USCXsJ1NqgbDCssgxFNaAnQItndMmwMLZmbE-FASerNMeCgOVDugDHpFs2SkFLIHQkHbQr8jRANDkgGD0058J6CPMdEWYgw_L_Hlwwy7e66_2rfd7r9ndVAeap5v9Nm53H-t69x0Fj8fKeKqMp8qOhPzn-wEoj1Fh</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>599PA VALIDATION OF CURRENT PROGNOSTIC SCORES IN METASTATIC COLORECTAL CANCER (MCRC) AND A NEW PROGNOSTIC SCORE (A GEMCAD STUDY)</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Alonso-Orduna, V. ; Marmol, M. ; Escudero, P. ; Salud, A. ; Safont, M.J. ; Méndez, J.C. ; Girón, C. García ; Martín, M. ; Fernandez-Martos, C. ; Albéniz, X. García ; Feliu, J. ; Maurel, J.</creator><creatorcontrib>Alonso-Orduna, V. ; Marmol, M. ; Escudero, P. ; Salud, A. ; Safont, M.J. ; Méndez, J.C. ; Girón, C. García ; Martín, M. ; Fernandez-Martos, C. ; Albéniz, X. García ; Feliu, J. ; Maurel, J.</creatorcontrib><description>Abstract Aim: Background: The two main prognostic scores for mCRC (Kohne and GERCOR) do not account for resectability of liver-only metastasis (LiM) and thus are limited as treatment guidance. We propose a classification of patients based on LiM resectability, performance status (PS) and lactate dehydrogenase (LDH) levels and compare its discrimination capacity against Kohne and GERCOR scores. Methods: We analyzed 395 patients treated with first-line oxaliplatin-based regimes with or without monoclonal antibodies. Patients were classified as stage 1 if LiM were considered resectable (&lt;4 nodules and &lt;5 cm diameter) or potentially resectable (&gt;4 and &lt;10 nodules or &gt;5 cm diameter), PS 0-1 and LDH &lt; 1.5 ULN; stage 2 if LiM were not resectable or with extrahepatic spread, PS 0-1 and LDH &lt; 1.5 ULN; stage 3 if PS 2 or LDH &gt; 1.5 ULN. This score, Kohne, and GERCOR scores were tested for discrimination using Harrel's C index (HCI, higher is better) and calibration using Akaike information criterion (AIC, smaller is better) of progression-free survival (PFS) and overall survival (OS). Results: Group 1Group 2Group 3GEMCADN78206111PFS HR (95% CI)1 (Reference)2.07 (1.54-2.78)2.98 (2.15-4.13)PFS HCI (95% CI)0.66 (0.60-0.73)PFS AIC3496.2OS HR (95% CI)1 (Reference)2.14 (1.52-3.00)3.68 (2.55-5.32)OS HCI (95% CI)0.68 (0.62-0.73)OS AIC2903.7KohneN15920531PFS HR (95% CI)1 (Reference)1.55 (1.23-1.93)2.86 (1.89-4.31)PFS HCI (95% CI)0.62 (0.56-0.68)PFS AIC3515.7OS HR (95% CI)1 (Reference)1.63 (1.27-2.10)4.57 (2.93-7.13)OS HCI (95% CI)0.65 (0.60-0.71)OS AIC2915.4GERCORN116153126PFS HR (95% CI)1 (Reference)1.40 (1.08-1.82)2.04 (1.55-2.68)PFS HCI (95% CI)0.60 (0.54-0.66)AIC3517.7OS HR (95% CI)1 (Reference)2.19 (1.62-2.96)3.21 (2.34-4.40)OS HCI (95% CI)0.66 (0.62-0.71)OS AIC2898.4 Conclusions: Conclusions. GEMCAD score performs as well, if not better, than Kohne and GERCOR scores and allows treatment guidance. Disclosure: All authors have declared no conflicts of interest.</description><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdu333.101</identifier><language>eng</language><publisher>Oxford University Press</publisher><ispartof>Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv204-iv204</ispartof><rights>European Society for Medical Oncology 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. 2014</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Alonso-Orduna, V.</creatorcontrib><creatorcontrib>Marmol, M.</creatorcontrib><creatorcontrib>Escudero, P.</creatorcontrib><creatorcontrib>Salud, A.</creatorcontrib><creatorcontrib>Safont, M.J.</creatorcontrib><creatorcontrib>Méndez, J.C.</creatorcontrib><creatorcontrib>Girón, C. García</creatorcontrib><creatorcontrib>Martín, M.</creatorcontrib><creatorcontrib>Fernandez-Martos, C.</creatorcontrib><creatorcontrib>Albéniz, X. García</creatorcontrib><creatorcontrib>Feliu, J.</creatorcontrib><creatorcontrib>Maurel, J.</creatorcontrib><title>599PA VALIDATION OF CURRENT PROGNOSTIC SCORES IN METASTATIC COLORECTAL CANCER (MCRC) AND A NEW PROGNOSTIC SCORE (A GEMCAD STUDY)</title><title>Annals of oncology</title><description>Abstract Aim: Background: The two main prognostic scores for mCRC (Kohne and GERCOR) do not account for resectability of liver-only metastasis (LiM) and thus are limited as treatment guidance. We propose a classification of patients based on LiM resectability, performance status (PS) and lactate dehydrogenase (LDH) levels and compare its discrimination capacity against Kohne and GERCOR scores. Methods: We analyzed 395 patients treated with first-line oxaliplatin-based regimes with or without monoclonal antibodies. Patients were classified as stage 1 if LiM were considered resectable (&lt;4 nodules and &lt;5 cm diameter) or potentially resectable (&gt;4 and &lt;10 nodules or &gt;5 cm diameter), PS 0-1 and LDH &lt; 1.5 ULN; stage 2 if LiM were not resectable or with extrahepatic spread, PS 0-1 and LDH &lt; 1.5 ULN; stage 3 if PS 2 or LDH &gt; 1.5 ULN. This score, Kohne, and GERCOR scores were tested for discrimination using Harrel's C index (HCI, higher is better) and calibration using Akaike information criterion (AIC, smaller is better) of progression-free survival (PFS) and overall survival (OS). Results: Group 1Group 2Group 3GEMCADN78206111PFS HR (95% CI)1 (Reference)2.07 (1.54-2.78)2.98 (2.15-4.13)PFS HCI (95% CI)0.66 (0.60-0.73)PFS AIC3496.2OS HR (95% CI)1 (Reference)2.14 (1.52-3.00)3.68 (2.55-5.32)OS HCI (95% CI)0.68 (0.62-0.73)OS AIC2903.7KohneN15920531PFS HR (95% CI)1 (Reference)1.55 (1.23-1.93)2.86 (1.89-4.31)PFS HCI (95% CI)0.62 (0.56-0.68)PFS AIC3515.7OS HR (95% CI)1 (Reference)1.63 (1.27-2.10)4.57 (2.93-7.13)OS HCI (95% CI)0.65 (0.60-0.71)OS AIC2915.4GERCORN116153126PFS HR (95% CI)1 (Reference)1.40 (1.08-1.82)2.04 (1.55-2.68)PFS HCI (95% CI)0.60 (0.54-0.66)AIC3517.7OS HR (95% CI)1 (Reference)2.19 (1.62-2.96)3.21 (2.34-4.40)OS HCI (95% CI)0.66 (0.62-0.71)OS AIC2898.4 Conclusions: Conclusions. GEMCAD score performs as well, if not better, than Kohne and GERCOR scores and allows treatment guidance. Disclosure: All authors have declared no conflicts of interest.</description><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNqVz09LAzEQh-EgCq7aD-Btji24Nmm61RyH2bRd2E1KklY8hcU_oNht6dKDNz96t9SbJ08DD8MPXsZuBb8XXMlh3TSb5mW4ft1LKTsSZywR2USlj3wszlnC1UimD5kcX7Krtv3knE_USCXsJ1NqgbDCssgxFNaAnQItndMmwMLZmbE-FASerNMeCgOVDugDHpFs2SkFLIHQkHbQr8jRANDkgGD0058J6CPMdEWYgw_L_Hlwwy7e66_2rfd7r9ndVAeap5v9Nm53H-t69x0Fj8fKeKqMp8qOhPzn-wEoj1Fh</recordid><startdate>20140901</startdate><enddate>20140901</enddate><creator>Alonso-Orduna, V.</creator><creator>Marmol, M.</creator><creator>Escudero, P.</creator><creator>Salud, A.</creator><creator>Safont, M.J.</creator><creator>Méndez, J.C.</creator><creator>Girón, C. García</creator><creator>Martín, M.</creator><creator>Fernandez-Martos, C.</creator><creator>Albéniz, X. García</creator><creator>Feliu, J.</creator><creator>Maurel, J.</creator><general>Oxford University Press</general><scope/></search><sort><creationdate>20140901</creationdate><title>599PA VALIDATION OF CURRENT PROGNOSTIC SCORES IN METASTATIC COLORECTAL CANCER (MCRC) AND A NEW PROGNOSTIC SCORE (A GEMCAD STUDY)</title><author>Alonso-Orduna, V. ; Marmol, M. ; Escudero, P. ; Salud, A. ; Safont, M.J. ; Méndez, J.C. ; Girón, C. García ; Martín, M. ; Fernandez-Martos, C. ; Albéniz, X. García ; Feliu, J. ; Maurel, J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-oup_primary_10_1093_annonc_mdu333_1013</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Alonso-Orduna, V.</creatorcontrib><creatorcontrib>Marmol, M.</creatorcontrib><creatorcontrib>Escudero, P.</creatorcontrib><creatorcontrib>Salud, A.</creatorcontrib><creatorcontrib>Safont, M.J.</creatorcontrib><creatorcontrib>Méndez, J.C.</creatorcontrib><creatorcontrib>Girón, C. García</creatorcontrib><creatorcontrib>Martín, M.</creatorcontrib><creatorcontrib>Fernandez-Martos, C.</creatorcontrib><creatorcontrib>Albéniz, X. García</creatorcontrib><creatorcontrib>Feliu, J.</creatorcontrib><creatorcontrib>Maurel, J.</creatorcontrib><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Alonso-Orduna, V.</au><au>Marmol, M.</au><au>Escudero, P.</au><au>Salud, A.</au><au>Safont, M.J.</au><au>Méndez, J.C.</au><au>Girón, C. García</au><au>Martín, M.</au><au>Fernandez-Martos, C.</au><au>Albéniz, X. García</au><au>Feliu, J.</au><au>Maurel, J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>599PA VALIDATION OF CURRENT PROGNOSTIC SCORES IN METASTATIC COLORECTAL CANCER (MCRC) AND A NEW PROGNOSTIC SCORE (A GEMCAD STUDY)</atitle><jtitle>Annals of oncology</jtitle><date>2014-09-01</date><risdate>2014</risdate><volume>25</volume><issue>suppl_4</issue><spage>iv204</spage><epage>iv204</epage><pages>iv204-iv204</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><abstract>Abstract Aim: Background: The two main prognostic scores for mCRC (Kohne and GERCOR) do not account for resectability of liver-only metastasis (LiM) and thus are limited as treatment guidance. We propose a classification of patients based on LiM resectability, performance status (PS) and lactate dehydrogenase (LDH) levels and compare its discrimination capacity against Kohne and GERCOR scores. Methods: We analyzed 395 patients treated with first-line oxaliplatin-based regimes with or without monoclonal antibodies. Patients were classified as stage 1 if LiM were considered resectable (&lt;4 nodules and &lt;5 cm diameter) or potentially resectable (&gt;4 and &lt;10 nodules or &gt;5 cm diameter), PS 0-1 and LDH &lt; 1.5 ULN; stage 2 if LiM were not resectable or with extrahepatic spread, PS 0-1 and LDH &lt; 1.5 ULN; stage 3 if PS 2 or LDH &gt; 1.5 ULN. This score, Kohne, and GERCOR scores were tested for discrimination using Harrel's C index (HCI, higher is better) and calibration using Akaike information criterion (AIC, smaller is better) of progression-free survival (PFS) and overall survival (OS). Results: Group 1Group 2Group 3GEMCADN78206111PFS HR (95% CI)1 (Reference)2.07 (1.54-2.78)2.98 (2.15-4.13)PFS HCI (95% CI)0.66 (0.60-0.73)PFS AIC3496.2OS HR (95% CI)1 (Reference)2.14 (1.52-3.00)3.68 (2.55-5.32)OS HCI (95% CI)0.68 (0.62-0.73)OS AIC2903.7KohneN15920531PFS HR (95% CI)1 (Reference)1.55 (1.23-1.93)2.86 (1.89-4.31)PFS HCI (95% CI)0.62 (0.56-0.68)PFS AIC3515.7OS HR (95% CI)1 (Reference)1.63 (1.27-2.10)4.57 (2.93-7.13)OS HCI (95% CI)0.65 (0.60-0.71)OS AIC2915.4GERCORN116153126PFS HR (95% CI)1 (Reference)1.40 (1.08-1.82)2.04 (1.55-2.68)PFS HCI (95% CI)0.60 (0.54-0.66)AIC3517.7OS HR (95% CI)1 (Reference)2.19 (1.62-2.96)3.21 (2.34-4.40)OS HCI (95% CI)0.66 (0.62-0.71)OS AIC2898.4 Conclusions: Conclusions. GEMCAD score performs as well, if not better, than Kohne and GERCOR scores and allows treatment guidance. Disclosure: All authors have declared no conflicts of interest.</abstract><pub>Oxford University Press</pub><doi>10.1093/annonc/mdu333.101</doi></addata></record>
fulltext fulltext
identifier ISSN: 0923-7534
ispartof Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv204-iv204
issn 0923-7534
1569-8041
language eng
recordid cdi_oup_primary_10_1093_annonc_mdu333_101
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
title 599PA VALIDATION OF CURRENT PROGNOSTIC SCORES IN METASTATIC COLORECTAL CANCER (MCRC) AND A NEW PROGNOSTIC SCORE (A GEMCAD STUDY)
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T00%3A56%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=599PA%20VALIDATION%20OF%20CURRENT%20PROGNOSTIC%20SCORES%20IN%20METASTATIC%20COLORECTAL%20CANCER%20(MCRC)%20AND%20A%20NEW%20PROGNOSTIC%20SCORE%20(A%20GEMCAD%20STUDY)&rft.jtitle=Annals%20of%20oncology&rft.au=Alonso-Orduna,%20V.&rft.date=2014-09-01&rft.volume=25&rft.issue=suppl_4&rft.spage=iv204&rft.epage=iv204&rft.pages=iv204-iv204&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdu333.101&rft_dat=%3Coup%3E10.1093/annonc/mdu333.101%3C/oup%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/annonc/mdu333.101&rfr_iscdi=true